H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

September 8, 2026 7:38 AM

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $8.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented:"We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found